BioInfra Co.,Ltd. Logo

BioInfra Co.,Ltd.

Develops multi-biomarker blood tests for early cancer screening and gene treatments.

199730 | KO

Overview

Corporate Details

ISIN(s):
KR7199730003
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 흥덕중앙로 120 4층, 5층, 용인시

Description

BioInfra Co., Ltd. is a biotechnology and healthcare company specializing in innovative solutions for disease prevention and early detection, with a primary focus on oncology. The company's core technology is a proprietary multi-biomarker blood test for the early screening of eight major cancers, including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer. This in vitro diagnostic tool analyzes a small blood sample to assess cancer risk, aiming to improve patient outcomes through early intervention. Beyond diagnostics, BioInfra also engages in pharmaceutical research and development, offering clinical research services and developing cancer gene treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-30 00:00
임시주주총회결과
Korean HTML 5.1 KB
2025-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2025-08-13 00:00
반기보고서 (2025.06)
Korean HTML 763.0 KB
2025-06-05 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 83.8 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 754.8 KB
2025-03-25 00:00
정기주주총회결과
Korean HTML 30.2 KB
2025-03-14 00:00
감사보고서제출
Korean HTML 18.1 KB
2025-03-14 00:00
[기재정정]주주총회소집공고
Korean HTML 103.0 KB
2025-03-14 00:00
사업보고서 (2024.12)
Korean HTML 933.5 KB
2025-03-10 00:00
현금ㆍ현물배당결정
Korean HTML 8.3 KB
2025-03-10 00:00
주주총회소집결의
Korean HTML 16.5 KB
2025-03-10 00:00
주주총회소집공고
Korean HTML 100.1 KB
2025-02-06 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean HTML 11.0 KB
2024-12-10 00:00
주주명부폐쇄기간또는기준일설정
Korean HTML 4.1 KB
2024-12-03 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.3 KB

Automate Your Workflow. Get a real-time feed of all BioInfra Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioInfra Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioInfra Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aptahem AB Logo
A clinical-stage biotech developing aptamer-based drugs for life-threatening conditions.
Sweden
APTA
APTAMER GROUP PLC Logo
Develops custom affinity binders for research, diagnostics, and therapeutics.
United Kingdom
APTA
Aptevo Therapeutics Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for cancer.
United States of America
APVO
Biotech firm providing MICROPIG models, bio-resources, and non-clinical CRO services.
South Korea
149300
Aran Research & Development (1982) Ltd. Logo
A product design and development firm providing services from concept to manufacturing.
Israel
ARAN
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
ARVINAS, INC. Logo
Clinical-stage biopharma developing therapeutics based on targeted protein degradation.
United States of America
ARVN
Asarina Pharma AB Logo
A biotechnology company in liquidation, formerly focused on neurosteroid therapies.
Sweden
ASAP
Atara Biotherapeutics, Inc. Logo
Develops off-the-shelf allogeneic T-cell immunotherapies for cancer and autoimmune diseases.
United States of America
ATRA
An integrated biologics development partner offering services from DNA sequence to cell bank.
South Korea
355690

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.